

"State of the Clinical Trials Industry: A Sourcebook of Charts and Statistics, 2007"

Thomson CenterWatch, 2007, 432 pages, \$599.00

Review by Norman M. Goldfarb

"State of the Clinical Trials Industry: A Sourcebook of Charts and Statistics, 2007" demonstrates why CenterWatch continues to be the most-quoted source of information about clinical research. The 2007 edition is 50% bigger in pages (432) and 75% bigger in tables and charts (537) than the 2005 edition. Most of the figures are based on original

This book has been selected for
[The First Clinical Research Bookshelf](#)
Essential reading for clinical research professionals

CenterWatch research. The half-page charts have a clean, consistent format, with each bar or slice of pie accompanied by a number. Articles from CenterWatch newsletters provide context for the data.

The book includes 11 chapters (with number of tables and charts):

- 2006 in Review (0)
- Industry Sales (44)
- R&D Expenditure (35)
- Clinical Development (69)
- Eyes On and Pipelines (12)
- Sponsors (36)
- Contract Research Organizations (52)
- Outsourcing (66)
- Investigative Site Infrastructure and Operations (63)
- Study Volunteers (71)
- Regulatory (89)

Statistical tidbits include:

- Ethical pharmaceutical sales by PhRMA members increased only 3.5% in 2005, after growing an average of 10.7% over the preceding five years.
- In 2004, the industry reversed its alarming decline of FDA NME approvals (36, up from 18 and 19 in the previous two years). But, with an estimated 20 NME approvals in 2005, the industry returned to form, despite U.S. R&D expenditures that grew to \$31.4 billion.
- From 2000 to 2004, PhRMA member spending on clinical development ballooned 79% for Phase I, 100% for Phase II, 213% for Phase III, and 345% for Phase IV.
- Only 22% of IND drugs obtain FDA marketing approval. 56% of drugs that enter Phase II testing do not enter Phase III. 32% of drugs that enter Phase III testing do not reach the market.
- From 2000 to 2005, the number of pediatric drugs in active development has steadily declined from 217 to 146.

The book is available at www.centerwatch.com.

Reviewer

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Contact him at 1.650.465.0119 or ngoldfarb@firstclinical.com.